3-Fluoro-7-oxa-4,12,15,20,22,23-hexazatetracyclo[14.5.2.12,6.019,22]tetracosa-1(21),2,4,6(24),16(23),17,19-heptaen-11-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 3-Fluoro-7-oxa-4,12,15,20,22,23-hexazatetracyclo[14.5.2.12,6.019,22]tetracosa-1(21),2,4,6(24),16(23),17,19-heptaen-11-one
• 英文别名: 3-fluoro-7-oxa-4,12,15,20,22,23-hexazatetracyclo[14.5.2.12,6.019,22]tetracosa-1(21),2,4,6(24),16(23),17,19-heptaen-11-one
• 化学式: C₁₇H₁₇FN₆O₂
• 分子量: 356.4
• InChiKey: AJYPHPYAJCKZLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  93.4
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• MACROCYCLIC LRRK2 KINASE INHIBITORS
  申请人：ONCODESIGN S.A.

  公开号：US20140206683A1

  公开（公告）日：2014-07-24

  The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
• US9096609B2
  申请人：——

  公开号：US9096609B2

  公开（公告）日：2015-08-04
• US9370520B2
  申请人：——

  公开号：US9370520B2

  公开（公告）日：2016-06-21